Literature DB >> 30962062

Infective Endocarditis in the Intravenous Drug Use Population at a Tertiary Hospital in Melbourne, Australia.

Adelene Hilbig1, Allen Cheng2.   

Abstract

Background Infective endocarditis has been associated with underlying cardiac pathology and streptococci infections. Intravenous drug use (IVDU) is increasingly implicated as a contributing factor, resulting in a shift to a younger patient demographic, tricuspid valve involvement, severe staphylococcal infection, and unique management challenges. The objective of this study was to describe the clinical features, management and outcomes of patients with IVDU-associated infective endocarditis in the Australian context. Methods A retrospective review of all episodes of IVDU-associated infective endocarditis at a tertiary hospital in Melbourne, Australia, from 2008 to 2015, was conducted. Included cases met Duke Criteria for 'definite' or 'possible' infective endocarditis, and had a history of IVDU within 3 months of presentation. Demographic data, substance use history, clinical features, surgical intervention, follow-up, and mortality data was collected. We explored factors associated with surgical intervention, recurrence and mortality. Results Fifty-five (55) episodes of IVDU-associated infective endocarditis were identified in 46 patients; the median age was 40 years and 58% were male. The tricuspid valve was most commonly affected (38%), and left heart pathology was documented in 53% of cases. Methicillin-sensitive Staphylococcus aureus was the most common pathogen (67%). Thirty-six (36%) per cent of patients underwent surgical intervention, and all patients received antibiotics as a component of treatment, with a median duration of 42 days (IQR 21, 42 days). Heart failure and a vegetation larger than 1 cm were significantly associated with surgical intervention. Total mortality was 14.5%; surgical mortality was 10%. Opioid replacement therapy and the absence of psychiatric co-morbidities were protective factors for surgical intervention and disease recurrence. Conclusions In contrast to common perception, left-sided endocarditis was more common than tricuspid valve endocarditis. Left heart pathology is typically a more severe clinical entity, however, our study determined mortality rates remained similar when compared to right heart pathology. Further research is required to assess rates of left sided disease in the IVDU population, and elucidate the relationship between IVDU and left heart pathology.
Copyright © 2019 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Infective endocarditis; Intravenous drug use (IVDU); Left heart pathology; Surgery

Year:  2019        PMID: 30962062     DOI: 10.1016/j.hlc.2018.12.016

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  3 in total

1.  Epidemiologic and clinical characteristics of infective endocarditis: a single-center retrospective study in the Bronx, New York.

Authors:  Wasla Liaqat; Leonidas Palaiodimos; Weijia Li; Dimitrios Karamanis; Arooj Tahir; Andreas Tzoumas; Sanjana Nagraj; Nidhish Tiwari; Michael Grushko; Damianos Kokkinidis; Eleonora Gashi; Jason Leider; Christina Coyle; Robert T Faillace
Journal:  Infection       Date:  2022-05-25       Impact factor: 7.455

Review 2.  The quest for the optimal surgical management of tricuspid valve endocarditis in the current era: a narrative review.

Authors:  Francesco Nappi; Cristiano Spadaccio; Christos Mihos; Kasra Shaikhrezai; Christophe Acar; Marc R Moon
Journal:  Ann Transl Med       Date:  2020-12

3.  Characteristics and outcomes of patients with right-sided endocarditis undergoing cardiac surgery.

Authors:  Carolyn Weber; Asmae Gassa; Kaveh Eghbalzadeh; Julia Merkle; Ilija Djordjevic; Johanna Maier; Anton Sabashnikov; Antje-Christin Deppe; Elmar W Kuhn; Parwis B Rahmanian; Oliver J Liakopoulos; Thorsten Wahlers
Journal:  Ann Cardiothorac Surg       Date:  2019-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.